NewLimit Raises $435m for Liver Trials, and Other Financings
The startup said the round will fund its epigenetic reprogramming work and support a first clinical trial for a liver medicine.
- Longevity startup NewLimit raised $435 million in a Series C round on Tuesday to launch its first clinical trial for a liver reprogramming therapy next year.
- Founded in 2021, NewLimit was established by Coinbase CEO Brian Armstrong, venture capitalist Blake Byers, and CEO Jacob Kimmel to develop epigenetic reprogramming therapies for reversing cellular age.
- The Series C values NewLimit at $3.1 billion, making it one of the largest biotech rounds this year. Founders Fund led the financing, joined by Thrive Capital, Eli Lilly Ventures, Greenoaks, and Quiet Capital.
- Kimmel cited "the breakthrough discovery of a prototype medicine that reverses cell age" as the driver for accelerating the timeline. The funding enables the company to advance its lead candidate into human testing.
- NewLimit expects its liver therapy to accelerate recovery from injury and dietary damage. "Our trial next year will reveal how liver age reprogramming translates into humans for the first time," Kimmel said.
10 Articles
10 Articles
Longevity startup NewLimit raises $435 million ahead of first clinical trial
Longevity startup NewLimit plans to launch its first clinical trial of a liver medicine after raising a staggering $435 million in new funding. NewLimit announced its plans and Series C fundraising Tuesday. Founders Fund, the noted Silicon Valley venture capital firm co-founded by Peter Thiel, led the financing, which also included Thrive Capital, Lilly Ventures, and money from tech entrepreneurs Nat Friedman and Daniel Gross. The company is now…
Coinbase CEO Brian Armstrong’s Newlimit Secures $435M, Soaring to a $3.1B Valuation
TL;DR: Newlimit raised $435 million in a Series C round led by Founders Fund, lifting its valuation to about $3.1 billion. The longevity biotech, co-founded by Brian Armstrong, Blake Byers and Mark Kimmel, is developing epigenetic reprogramming medicines to restore youthful cell function. After a prototype breakthrough in old human liver cells, Newlimit plans human clinical trials next year, shifting attention from funding momentum to clinical …
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
